Allos Therapeutics (ALTH) Reports Q2 Profit of 2c/Share
Tweet
Share
E-mailGet Alerts ALTH Hot Sheet
Price: $1.84 --0%
Financial Fact:
Operating income (loss): -11.32M
Today's EPS Names:
OFLX, AFIB, NMRD, More
Financial Fact:
Operating income (loss): -11.32M
Today's EPS Names:
OFLX, AFIB, NMRD, More
Join SI Premium – FREE
Allos Therapeutics (NASDAQ: ALTH) reported Q2 EPS of $0.02, $0.16 better than the analyst estimate of ($0.14). Revenue for the quarter came in at $11 million versus the consensus estimate of $11.91 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 3c
- Eton Pharmaceuticals Inc. (ETON) Tops Q2 EPS by 28c, Raises Guidance
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
